Rocket Pharmaceuticals competitors

Laurent Fischer joined Tobira's Board of Directors in April 2009 and became Chief Executive Officer in 2014. Laurent Fischer brings 20 years of drug development and commercialization experience in the biopharmaceutical industry. Prior to joining Tobira full time he was Chairman and Chief Executive Officer of Jennerex Inc., a private, clinical-stage biotherapeutics company focused on the design, development and commercialization of first-in-class, breakthrough targeted oncolytic immunotherapy products for cancer that was sold for up to $150 million. Prior to Jennerex, he was co-founder, president and CEO of Ocera Therapeutics (NASDAQ: OCRX), where he licensed and developed OCR-002 the first ammonia scavenger for the treatment of complications of liver disease and oversaw the approval of Zysa®, the first treatment approved for irritable bowel syndrome in Europe. Laurent Fischer has co-founded and managed four healthcare companies and held senior management positions at DuPont-Merck, DuPont Pharmaceuticals, and Hoffmann-La Roche in liver disease, virology and oncology. Laurent Fischer was responsible for the global launch of Sustiva® the first once-daily anti-HIV therapy, now part of the fixed dose combination therapy Atripla® and was involved in the launch of Invirase®, the first protease inhibitor, in the United States. Laurent Fischer received his undergraduate degree from the University of Geneva and his medical degree from the Geneva Medical School, Switzerland.

Nick Leschly has served as our chief bluebird since September 2010. Formerly, Nick was a partner and founding member of Third Rock Ventures in 2007. Nick played an integral role in the overall formation, development and business strategy of several of Third Rock’s portfolio companies, including Agios Pharmaceuticals, Inc. and Edimer Pharmaceuticals, Inc. Prior to joining Third Rock, he worked at Millennium Pharmaceuticals, leading several early-stage drug development programs and served as the product leader for VELCADE. Nick also founded and served as chief executive officer of MedXtend Corporation. He received his B.S. in molecular biology from Princeton University and his MBA from Wharton Business School. He currently serves as a board member of the Biotechnology Innovation Organization (BIO) and Synlogic Therapeutics.

President, Chief Executive Officer and Director of SCYNEXIS Inc. (Nasdaq: SCYX) and Director of various public companies and non-profit organizationsCompleted several successful rounds of financing and company restructuringExperience as a Director in Boards of public companies (Audit Committee, Compensation Committee and Governance & Nominating Committee) Managed groups up to 1,600 employees in global organizations and R&D budgets up to $950MM/yearOver 35 products approved through various regulatory paths [505(b)1, 505(b)2, 510(k) devices and ANDA] in the US and globally in Europe and South America:Anti-Infectives: Cedax (ceftibuten, Global), Isepacin (isepamicina - Europe), Cleeravue-M (minocycline for skin infections - US), Teflaro (ceftaroline - US), Colobreathe (Inhaled Colistin for cystic fibrosis - Europe), Avycaz (Ceftazidime/Avibactam)Oncology: Intro-A (Interferon-α in Non-Hodgkin lymphoma - US), Fareston (toremifene for breast cancer -US), Temodar (Temozolomide for brain tumors- Global) Central Nervous System: Subutex (buprenorphine for opioid addictions, Global), Savella (milnacipran for fibromyalgia - US), Lexapro pediatric (escitalopram - US), Namenda XR (memantine for Alzheimer disease, US), Fetzima (levomilnacipran for Major Depression Disorder - Global) Cardiovascular: Bystolic (nebivolol for hypertension - US)Gastroenterology: Linzess (linaclotide for IBSc and CIC - US)Respiratory Medicine: Daliresp (roflumilast for COPD - US), Tudorza (Aclidinium for COPD - US)Dermatology: Lotrisone Lotion (US for eczema), Mometasone Pediatric (US), MimyX (US), Duac (Global), Ciclopirox Shampoo (Global), Ciclopirox solution (Global), Rosac Wash (US), Brevoxyl Pads (US), Levulan (Global)Generics (US): Griseofulvin Suspension, Sodium Sulfacetamide Wash, Urea CreamOTC/Cosmeceuticals: Physiogel sunscreen (International), PanOxyl 10%, Foaming Acne Wash, Clariderm (International), Mimyx (US), SunMAX line (International), LactiCare HC (International)

J have worked as Chairman/Pres/CEO/Secy/Co-Founder at Genprex Inc. They work or have worked as MEMBER at STATE BAR OF TEXAS. J attended TAMU and University of Texas School of Law.

Dr. Rienhoff is a physician, entrepreneur and founder of several biotech and presently serves as CEO of Imago BioSciences. Dr. Rienhoff was the founder and CEO of FerroKin Biosciences, a development stage company that was acquired by Shire in for $325 million in 2012. He has more than 20 years experience as both a venture investor and entrepreneur in the life science sector. He was a partner at New Enterprise Associates and later, a director of Abingworth Management Ltd., running their US operation. Dr. Rienhoff is an Adjunct Scientist at the Children's Hospital Oakland Research Institute. He received his M.D. from the Johns Hopkins University School of Medicine and his B.A. from Williams College.

Dr. Bruce A. Goldsmith is the Interim CEO at Civetta Therapeutics and Venture Partner at Deerfield Management. He joined Lycera as chief business officer in 2013 and brings more than 15 years of experience in the pharmaceutical and biotechnology industries. Most recently, he served as senior vice president corporate development at Allos Therapeutics, where he helped shape and manage corporate strategy and planning, financing transactions, business development and investor relations. While at Allos, Dr. Goldsmith led the successful sale of the company and, previously, executed a global collaboration for the co-development and commercialization of the company’s lead oncology asset outside of North America. Prior to joining Allos, Dr. Goldsmith served as vice president, strategic marketing at GPC Biotech. Previously, he held various strategic marketing and business development roles with the Johnson & Johnson family of companies, including roles as group product director, virology and global marketing leader, oncology. Dr. Goldsmith holds an M.B.A. from Columbia Business School, a Ph.D. in neuroscience from the University of Pennsylvania and his B.A. in biology from Colgate University.